Laekna, Inc.
來凱醫藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2105)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

The Board of Laekna, Inc. is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended June 30, 2025, together with comparative figures for the same period of 2024, as follows.

In this announcement, "we" and "our" refer to the Company and where the context otherwise requires, the Group. Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments or have been rounded to one or two decimal places. Any discrepancies in any table, chart or elsewhere between totals and sums of amounts listed therein are due to rounding issues.

BUSINESS HIGHLIGHTS

We have made significant progress with respect to our clinical and pre-clinical candidate development and expansion of our product pipeline. For the six months ended June 30, 2025, we made the following milestones and achievements:

Advancing the Clinical Trials

LAE102 in Obesity, Phase I

LAE102 is our internally discovered monoclonal antibody against ActRIIA. Blocking Activin-ActRII pathway could promote muscle regeneration and fat mass reduction, this positions LAE102 as a promising drug candidate for achieving muscle preserving weight control. By the end of December 2024, the Group successfully completed the single ascending dose part of the Phase I clinical study (the "**SAD Study**") of LAE102 in China for the treatment of obesity.

A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m^2 and 23.08 kg/m^2 in Part A and Part B, respectively. Baseline demographic and clinical characteristics were generally balanced across the intravenous ("**IV**") and subcutaneous ("**SC**") cohorts of the study. Overall, LAE102 was well tolerated following a single IV or SC dose. No serious adverse events or treatment emergent adverse events ("**TEAEs**") leading to discontinuation of treatment were reported. The majority of the TEAEs were mild laboratory test abnormalities, which were asymptomatic and did not require medical intervention. There was no reported case of diarrhea. Activin A was significantly increased in 24 hours following a single intravenous or subcutaneous dose of LAE102. The duration of Activin A elevation was dose-dependent. The high-dose groups (8 mg/kg IV group, 16 mg/kg IV group, and 8 mg/kg SC group) maintained 2-to-3-fold increases above the baseline level through 28 days post-administration, indicating prolonged pathway blocking. The robust PK/PD correlation suggests potential efficacy and supports further clinical development of LAE102 in overweight and obese populations, which established a solid foundation for the Phase I multiple ascending dose study (the "**MAD Study**"). The detailed study results were presented at the 85th scientific sessions of the American Diabetes Association ("**ADA**") in June 2025.

The Group commenced study recruitment in the Phase I MAD Study of LAE102 in China by the end of March 2025. The Phase I MAD Study in China is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.

In November 2024, the Group entered into a clinical collaboration agreement with Eli Lilly and Company ("**Lilly**") (NYSE: LLY) to support and accelerate global clinical development of LAE102 for the treatment of obesity. Lilly will be responsible for the execution and funding of a Phase I study in the U.S. (the "**U.S. Phase 1 Clinical Trial**"). The Group retains global rights for LAE102. The Group submitted an Investigational New Drug (the "**IND**") amendment to the U.S. Food and Drug Administration (the "**U.S. FDA**") for LAE102 for the treatment of obesity in March 2025 and dosed the first subject in May 2025. The Group targets to achieve primary completion of the U.S. Phase I Clinical Trial in Q4 2025.

Laekna team has accumulated tremendous experience and extensive knowhow in this specific field and is developing, in addition to LAE102, more drug candidates to maximize the value of targeting ActRII receptors. LAE103 is an ActRIIB-selective antibody and LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody. Both are our internally discovered antibodies for muscle and other disease indications. IND-enabling studies of both antibodies have been initiated in 2024.

The results of the pre-clinical study of LAE102, LAE103 (an ActRIIB selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of ADA. LAE102, LAE103, and LAE123 are high-affinity functional antagonists. They can completely inhibit the signaling transduced by ligands such as activin A, B, AB, and MSTN, all of which are known to contribute to muscle atrophy. In addition, they also inhibit activin E and GDF3, which promote lipid accumulation of adipose tissue. In mouse models, LAE102 alone significantly induced muscle growth and reduced fat mass. Notably, a synergistic effect on muscle increase and fat loss was observed when combining LAE102 with LAE103, achieving the maximal effect comparable to the ActRIIA/IIB dual antagonistic monoclonal antibody LAE123. The findings indicate that ActRIIA is a major regulator of muscle growth and fat loss in mice. LAE102 shows great potential as muscle preserving weight loss management with a favorable safety profile. On the other hand, LAE123 could be utilized to treat diseases requiring complete inhibition of both ActRIIA and ActRIIB, such as spinal muscle atrophy.

We submitted IND application to the U.S. FDA for LAE103 by the end of June 2025 and obtained IND approval in July 2025. The Group targets to initiate phase I clinical study of LAE103 in the second half of 2025. In addition to LAE102, the phase I clinical studies of LAE103 enable us to separately evaluate the efficacy and safety of monoclonal antibodies targeting at ActRIIA and ActRIIB in humans. The Group also targets to advance LAE123 to phase I clinical studies in 2026. The Group has established a comprehensive ActRII portfolio and is actively advancing these drug candidates to clinical studies as novel therapies for muscle and other disease indications. We are in discussions with potential partners for strategic cooperations to accelerate development and commercialization of our ActRII portfolio.

LAE002 (afuresertib) + Fulvestrant in HR+/HER2-breast cancer, Phase III

The Group commenced the Phase III clinical trial AFFIRM-205 in China for LAE002 (afuresertib, an oral AKT inhibitor) plus fulvestrant in patients with PIK3CA/AKT1/PTEN alterations and HR+/HER2- locally advanced or metastatic breast cancer ("**LA/mBC**") (the "**Phase III Clinical Trial AFFIRM-205**") in May 2024. The Phase III Clinical Trial AFFIRM-205 is a multi- center, randomized, double-blind, placebo-controlled pivotal study to further assess the anti-tumor efficacy and safety of the combination therapy. Study recruitment is on track. The Group targets to complete subject enrollment in the fourth quarter of 2025 and to submit new drug application ("**NDA**") to CDE in the first half of 2026. We are in discussions with potential partners for strategic cooperations to accelerate regulatory approval and commercialization of LAE002 (afuresertib).

LAE002 (afuresertib) +LAE001/prednisone in mCRPC, Phase II

We completed a Phase II multi-region clinical trial of the study of LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 dual inhibitor) ("**LAE201**") in 40 patients with metastatic castration-resistant prostate cancer ("**mCRPC**") following standard of care ("**SOC**") treatment in 2024. The trial is an open-label, dose-escalation and dose expansion study to assess the efficacy and safety of the combination candidate. The study demonstrated promising treatment benefit for mCRPC patients. The median rPFS was 8.1 months. This is a significant improvement compared to the median rPFS of 2 to 4 months of mCRPC patients under the standard treatments historically. The combination therapy was generally tolerable with manageable treatment emergent adverse events and recoverable after routine treatments.

Design of the Phase III pivotal trial of LAE201 in patients with mCRPC following SOC treatment has been discussed with FDA. In May 2024, the Group has obtained approval from FDA for the protocol of this phase III clinical trial. We plan to pursue strategic partnerships to accelerate the development and commercialization of LAE002 (afuresertib) and LAE001 to address the great unmet medical need of the cancer therapeutic area.

Pre-clinical candidates (PCC)

For the six months ended June 30, 2025, IND application was submitted for LAE103 to the U.S. FDA by end of June 2025. The Group targets to initiate phase I clinical study of LAE103 in the second half of 2025. In addition to LAE102, the phase I clinical studies of LAE103 enable us to separately evaluate the efficacy and safety of monoclonal antibodies targeting at ActRIIA and ActRIIB in humans. We also target to advance LAE123 to phase I clinical study in 2026.

In the oncology area, LAE118, a PI3Kα mutant-selective inhibitor, has advanced to IND-enabling study in the fourth quarter of 2024. IND application for LAE120, an USP1 inhibitor, was filed with FDA in January 2025 and we received SMP (Study May Proceed) from FDA in February 2025. PCC declaration for LAE122, a WRN mutant-selective inhibitor, was also completed in March 2025.

Expected Upcoming Milestones in Second Half of 2025

About LAE102

- Preliminary results of Phase I MAD Study in China

- Preliminary results of U.S. Phase 1 Clinical Trial

About AFFIRM-205

- To complete subject enrollment of AFFIRM-205 Phase III China trial

Other Targeting ActRII Receptors

- To initiate phase I clinical study of LAE103

FINANCIAL HIGHLIGHTS

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Research and development expenses	**105,192**	126,148
Administrative expenses	**42,321**	30,380
Loss for the period	**129,637**	143,706
Total comprehensive loss for the period	**133,399**	138,548

Our research and development expenses decreased by RMB20.9 million or 16.6% from RMB126.1 million for the six months ended June 30, 2024 to RMB105.2 million for the six months ended June 30, 2025. Such decrease was primarily attributable to the milestone payment of RMB17.8 million incurred during the first half of 2024 relating to Phase III Clinical Trial AFFIRM-205, while no such expense was incurred during the Reporting Period.

Our administrative expenses increased by RMB11.9 million or 39.1% from RMB30.4 million for the six months ended June 30, 2024 to RMB42.3 million for the six months ended June 30, 2025, which was primarily attributable to increased equity settled share-based payment expenses.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended June 30, 2025 — unaudited

		Six months ended June 30,	
		2025	2024
	Note	***RMB'000***	*RMB'000*
Other income	*4*	**19,908**	14,149
Other losses		**–**	(4)
Administrative expenses		**(42,321)**	(30,380)
Research and development expenses		**(105,192)**	(126,148)
Loss from operations		**(127,605)**	(142,383)
Finance costs	*5(a)*	**(2,032)**	(1,323)
Loss before taxation	*5*	**(129,637)**	(143,706)
Income tax	*6*	**–**	–
Loss for the period		**(129,637)**	(143,706)
Other comprehensive income for the period (after tax and reclassification adjustments)			
Item that will not be reclassified to profit or loss:			
Exchange differences on translation of financial statements of the Company		**(9,216)**	11,962
Item that may be reclassified subsequently to profit or loss:			
Exchange differences on translation of financial statements of foreign subsidiaries		**5,454**	(6,804)
Total comprehensive income for the period		**(133,399)**	(138,548)
Loss per share	*7*		
Basic and diluted *(RMB)*		**(0.35)**	(0.40)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At June 30, 2025 — unaudited

	Note	**At June 30, 2025** ***RMB'000***	At December 31, 2024 *RMB'000*
Non-current assets			
Property, plant and equipment		**2,207**	2,686
Intangible assets	*8*	**123,725**	125,108
Right-of-use assets		**3,906**	4,774
Pledged deposits		**4,000**	–
Other non-current assets		**17,210**	14,068
		151,048	146,636
Current assets			
Prepayments and other receivables		**18,641**	13,368
Time deposits	*9*	**67,159**	163,611
Cash and cash equivalents	*10*	**676,562**	636,422
		762,362	813,401
Current liabilities			
Bank loans	*11*	**109,993**	99,010
Other payables	*12*	**82,667**	47,418
Lease liabilities		**2,045**	2,045
		194,705	148,473
Net current assets		**567,657**	664,928
Total assets less current liabilities		**718,705**	811,564
Non-current liabilities			
Lease liabilities		**2,349**	3,272
Deferred income		**3,500**	3,500
		5,849	6,772
NET ASSETS		**712,856**	804,792
CAPITAL AND RESERVES			
Share capital		**28**	28
Treasury shares		**(2)**	(2)
Reserves		**712,830**	804,766
TOTAL EQUITY		**712,856**	804,792

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

For the six months ended June 30, 2025 — unaudited

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Operating activities		
Cash used in operations	**(74,149)**	(143,382)
Net cash used in operating activities	**(74,149)**	(143,382)
Investing activities		
Payment for purchase of property, plant and equipment	**(71)**	(245)
Proceeds from sale of property, plant and equipment	**3**	4
Payment for purchase of intangible assets	**(440)**	(392)
Increase in pledged deposits	**(4,000)**	–
Decrease in time deposits with original maturity over three months	**95,437**	89,150
Interest received from bank deposits	**14,997**	13,318
Net cash generated from investing activities	**105,926**	101,835
Financing activities		
Proceeds from bank loans	**62,493**	42,290
Repayment of bank loans	**(51,510)**	(34,600)
Interest paid for bank loans	**(1,918)**	(1,167)
Proceeds from exercise of share options	**2,813**	–
Payment for capital element of lease liabilities	**(923)**	(792)
Payment for interest element of lease liabilities	**(114)**	(156)
Net cash generated from financing activities	**10,841**	5,575
Net increase/(decrease) in cash and cash equivalents	**42,618**	(35,972)
Cash and cash equivalents at January 1	**634,323**	440,815
Effect of foreign exchange rate changes	**(2,399)**	2,488
Cash and cash equivalents at June 30	**674,542**	407,331

NOTES TO THE UNAUDITED INTERIM FINANCIAL INFORMATION

(Expressed in Renminbi unless otherwise indicated)

1 GENERAL INFORMATION

The Company was incorporated in the Cayman Islands on July 29, 2016 as an exempted company with limited liability under the law of the Cayman Islands.

The Company is an investing holding company. The Group is principally engaged in discovering, developing and commercialising innovative therapies to patients with metabolic diseases, cancer and liver fibrosis around the world.

The Company's shares were listed on the Main Board of The Stock Exchange on June 29, 2023.

2 BASIS OF PREPARATION

This interim financial information has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with International Accounting Standard ("**IAS**") 34, *Interim financial reporting*, issued by the International Accounting Standards Board ("**IASB**"). It was authorised for issue on August 13, 2025.

The interim financial information has been prepared in accordance with the same accounting policies adopted in the 2024 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2025 annual financial statements. Details of any changes in accounting policies are set out in Note 3.

The preparation of an interim financial information in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

This interim financial information contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2024 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for a full set of financial statements prepared in accordance with IFRS Accounting Standards.

3 CHANGES IN ACCOUNTING POLICIES

The Group has applied the amendments to IAS 21, *The effects of changes in foreign exchange rates — Lack of exchangeability* issued by the IASB to this interim financial information for the current accounting period. The amendments do not have a material impact on this interim information as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

4 OTHER INCOME

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Interest income from bank deposits	**13,903**	13,318
Government grants	**4,509**	406
Net foreign exchange gains	**1,496**	425
	19,908	14,149

5 LOSS BEFORE TAXATION

Loss before taxation is arrived at after charging/(crediting):

(a) Finance costs

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Interest on bank loans	**1,918**	1,167
Interest on lease liabilities	**114**	156
	2,032	1,323

(b) Staff costs

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Salaries, wages and other benefits	**38,201**	43,935
Contributions to defined contribution retirement plan	**3,040**	2,580
Equity settled share-based payment expenses	**35,863**	10,797
	77,104	57,312

(c) Other items

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Amortisation of intangible assets	**1,098**	1,035
Depreciation charge		
— property, plant and equipment	**511**	708
— right-of-use assets	**868**	868
	1,379	1,576
Research and development expenses (i)	**105,192**	126,148
Net foreign exchange gains	**(1,496)**	(425)

(i) During the six months ended June 30, 2025, research and development expenses included RMB44,023,000 (six months ended June 30, 2024: RMB36,992,000) relating to staff costs and depreciation and amortisation expenses, which are also included in the respective total amounts disclosed separately above or in Note 5(b) for each of these types of expenses.

6 INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

(i) The Cayman Islands

Pursuant to the rules and regulations of the Cayman Islands, the Company is currently not subject to income tax.

(ii) Hong Kong, China

The Company's subsidiary incorporated in Hong Kong is subject to Hong Kong profits tax at 16.5% of the estimated assessable profits. No provision for Hong Kong profits tax had been made for the six months ended June 30, 2025 and 2024 as there were no assessable profits.

(iii) The U.S.

The Company's subsidiary incorporated in the U.S. is subject to Federal Tax at a rate of 21% and State Profits Tax at a rate of 0.75%–9.00% (2024: 0.75%–9.50%). Operations in the U.S. have incurred net accumulated operating losses for income tax purposes, and no income tax provisions had been made for the six months ended June 30, 2025 and 2024.

(iv) Chinese Mainland

Pursuant to the Corporate Income Tax Law of Chinese Mainland (the "**CIT**"), the Company's Chinese Mainland subsidiaries are subject to the CIT at a rate of 25%.

According to the new tax incentive policies promulgated by the State Tax Bureau of Chinese Mainland in March 2023, effective from January 1, 2023, an additional 100% of qualified research and development expenses incurred is allowed to be deducted from taxable income.

7 LOSS PER SHARE

The calculation of basic loss per share for the six months ended June 30, 2025 is based on the loss attributable to ordinary equity shareholders of the Company of RMB129,637,000 (six months ended June 30, 2024: RMB143,706,000) and the weighted average of 375,387,000 ordinary shares (six months ended June 30, 2024: 355,981,000 ordinary shares) in issue during the interim period.

The calculation of diluted loss per share for the six months ended June 30, 2025 and 2024 has not included the potential effects of share options and restricted share units issued by the Company, as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the six months ended June 30, 2025 and 2024 are the same as basic loss per share.

8 INTANGIBLE ASSETS

	In-licensed rights *RMB'000*	Software *RMB'000*	Total *RMB'000*
Cost:			
At January 1, 2025	122,512	7,807	130,319
Additions	–	223	223
Exchange adjustments	(508)	–	(508)
At June 30, 2025	122,004	8,030	130,034
Accumulated amortisation:			
At January 1, 2025	–	(5,211)	(5,211)
Charge for the period	–	(1,098)	(1,098)
At June 30, 2025	–	(6,309)	(6,309)
Net book value:			
At June 30, 2025	122,004	1,721	123,725
At January 1, 2025	122,512	2,596	125,108
Cost:			
At January 1, 2024	120,711	6,602	127,313
Exchange adjustments	752	–	752
At June 30, 2024	121,463	6,602	128,065
Accumulated amortisation:			
At January 1, 2024	–	(3,084)	(3,084)
Charge for the period	–	(1,035)	(1,035)
At June 30, 2024	–	(4,119)	(4,119)
Net book value:			
At June 30, 2024	121,463	2,483	123,946
At January 1, 2024	120,711	3,518	124,229

(a) In-licensed rights

The balance of in-licensed rights represents payments made to acquire development and commercialisation rights of drug products from third parties and are not ready for commercial use. Due to the inherent uncertainties in the research and development processes, these assets are particularly at risk of impairment if the projects are not expected to result in commercialised products. Key terms of these licenses are set out below:

(i) LAE001

On June 30, 2017, the Group entered into a license agreement with Novartis Pharma AG ("**Novartis**"), pursuant to which Novartis granted the Group an exclusive license to develop, manufacture and commercialise the licensed product LAE001 world widely.

Under the terms of the agreement, the Group made an one-time and non-refundable upfront payment of USD1 million (equivalent to RMB6.6 million) and granted 776,437 ordinary shares of the Company to Novartis (equaling to 7,764,370 shares after adjusting for the effect of the share subdivision upon the Listing). The Group capitalised an amount of USD1.8 million (equivalent to RMB12.2 million) in total. The Group also agreed to make regulatory milestone payments, as well as royalty payments on net sales to Novartis.

(ii) LAE002 (afuresertib) & LAE003

On May 9, 2018, the Group entered into a license agreement with Novartis, pursuant to which Novartis granted the Group an exclusive license to develop, manufacture and commercialise the licensed products LAE002 (afuresertib) and LAE003 world widely.

Under the terms of the agreement, the Group made an one-time and non-refundable upfront payment of USD5 million (equivalent to RMB31.9 million) and granted 165,200 ordinary shares of the Company to Novartis (equaling to 1,652,000 shares after adjusting for the effect of the share subdivision upon the Listing). The Group capitalised an amount of USD5.2 million (equivalent to RMB33.5 million) in total. The Group also agreed to make clinical trial milestone payments, regulatory milestone payments, sales milestone payments, as well as royalty payments on net sales to Novartis.

(iii) LAE005

On February 4, 2020, the Group entered into a license agreement with Novartis, pursuant to which Novartis granted the Group an exclusive license to develop, manufacture and commercialise the products LAE005 world widely.

Under the terms of the agreement, the Group made an one-time and non-refundable upfront payment of USD10 million (equivalent to RMB69.4 million) to Novartis and capitalised such payment. The Group also agreed to make clinical trial milestone payments, regulatory milestone payments, sales milestone payments, as well as royalty payments on net sales to Novartis.

9 TIME DEPOSITS

	At June 30, 2025	At December 31, 2024
	RMB'000	*RMB'000*
Bank deposits with original maturity over three months	**65,721**	161,158
Accrued interest	**1,438**	2,453
	67,159	163,611

10 CASH AND CASH EQUIVALENTS

	At June 30, 2025	At December 31, 2024
	RMB'000	*RMB'000*
Cash at banks	**204,070**	194,172
Deposits with banks	**470,472**	440,151
	674,542	634,323
Accrued interest	**2,020**	2,099
	676,562	636,422

As at June 30, 2025, cash and cash equivalents of the Group situated in Chinese Mainland amounted to RMB350,980,000 (2024: RMB259,738,000). Remittance of funds out of Chinese Mainland is subject to relevant rules and regulations of foreign exchange control.

11 BANK LOANS

	At June 30, 2025	At December 31, 2024
	RMB'000	*RMB'000*
Unsecured bank loans due within 1 year	**109,993**	99,010

As at June 30, 2025, unsecured bank loans carried interest at annual rates ranging from 2.37% to 3.85% (2024: 3.20% to 4.10%) per annum and were all repayable within one year.

12 OTHER PAYABLES

	At June 30, 2025	At December 31, 2024
	RMB'000	*RMB'000*
Payroll payables	**798**	13,456
Payables to grantees for exercise of share options (i)	**48,548**	–
Accrued research and development expenses	**28,991**	29,048
Other payables and accrued charges	**4,330**	4,914
	82,667	47,418

(i) As at June 30, 2025, the Group received payment of RMB48,548,000 through ESOP Trusts for and on behalf of certain grantees, being proceeds of the exercise of share options granted under the Pre-IPO Share Option Scheme and on-market sales of underlying shares of such share options exercised, including payables to the Company's key management personnel amounted to RMB20,237,000. Up to the date of this announcement, the balance had been fully settled by the Group.

13 DIVIDENDS

The directors of the Company did not propose any dividend during the six months ended June 30, 2025 (six months ended June 30, 2024: nil).

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

We are a science-driven, clinical-stage biotechnology company committed to bringing novel therapeutics to patients with metabolic diseases, cancer and liver fibrosis around the world. We focus on specific fields where we have accumulated tremendous experience and extensive know-how. As of June 30, 2025, we have initiated seven clinical trials for LAE102, LAE002 (afuresertib), LAE001 and LAE005 to address unmet medical needs in obesity and cancers.

We have assembled a seasoned management team with extensive experience and expertise covering the full cycle of drug discovery and development process, from pre-clinical asset discovery, clinical trial design and execution to regulatory process management and drug manufacturing. As of June 30, 2025, we were supported by a talented R&D team consisting of 60 employees, with 11 holding doctorate degrees and 33 holding master's degrees. Our core management team has established a long track record of accomplishment, leadership and deep knowledge in their respective fields.

Blocking Activin-ActRII pathway could promote muscle regeneration and fat mass reduction, this positions LAE102 as a promising drug candidate for achieving muscle preserving weight control. Laekna team has accumulated tremendous experience and extensive knowhow in this specific field and is developing, in addition to LAE102, more drug candidates to maximize the value of targeting ActRII receptors. LAE103 is an ActRIIB-selective antibody and LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody. Both of them are our internally discovered antibodies for muscle and other disease indications. We have established a comprehensive ActRII portfolio.

In the cancer area, we have built a comprehensive portfolio of drug candidates, including LAE002 (afuresertib), LAE001 and other seven pre-clinical drug candidates. LAE002 (afuresertib) is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the two AKT inhibitors in late-stage development for breast and prostate cancer globally. LAE002 (afuresertib) has demonstrated several superior features compared to other AKT inhibitors, including higher efficacy, better potency, more significant tumor inhibition exposure and a better safety profile, based on the public data. Capivasertib is the first approved AKT inhibitor from AstraZeneca, which FDA approved for HR+/HER2- breast cancer in November 2023. With the promising efficacy data from our LAE002 (afuresertib) Phase Ib study for HR+/HER2- breast cancer, the Group has initiated the Phase III pivotal study in China. The first subject in this Phase III study was enrolled in May 2024. The Group plans to bring this precision therapy to HR+/HER2- LA/mBC patients who are in need of novel treatment options.

We plan to pursue strategic partnerships to accelerate the development and commercialization of our drug candidates to address the great unmet medical needs.

MARKET OPPORTUNITIES IN OBESITY AND CANCER TREATMENTS

Globally, the number of people living with obesity is set to reach over 1.2 billion by 2030[1]. The causes of obesity are complex and, so often, it puts people on a path to other diseases — not only diabetes, but also heart and liver diseases, cancers and many more. There are growing understandings of the critical need to treat obesity among both the medical community and the public, while an increasing number of people living with such disease are actively seeking support.

Although the field of cancer treatment has progressed significantly in the past decade, a significant proportion of cancer patients find themselves in the absence of effective or safe treatments. The quality of life of those patients is severely affected, primarily attributable to SOC treatment resistance and/or intolerable toxicity, resulting in a large unmet medical need and a socioeconomic burden. Among those cancers of unmet medical need, HR+/HER2- metastatic breast cancer (HR+/HER2- mBC), mCRPC, PROC and triple negative breast cancer (TNBC) are some of the diseases with limited SOC options and unsatisfactory treatment outcomes.

[1] (World Obesity Federation, 2023b)

PIPELINE

The following chart summarizes the development status of our clinical and pre-clinical stage drug candidates as of the date of this announcement:



BUSINESS REVIEW

The Company has made significant progress during the six months ended June 30, 2025 with respect to its drug candidate pipeline and business operations, including the following milestones and achievements.

LAE102 in Obesity, Phase I

LAE102 is our internally discovered monoclonal antibody against ActRIIA. Blocking Activin-ActRII pathway could promote muscle regeneration and fat mass reduction, this positions LAE102 as a promising drug candidate for achieving muscle preserving weight control. By the end of December 2024, the Group successfully completed the SAD Study of LAE102 in China for the treatment of obesity.

A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m^2 and 23.08 kg/m^2 in Part A and Part B, respectively. Baseline demographic and clinical characteristics were generally balanced across the IV and SC cohorts of the study. Overall, LAE102 was well tolerated following a single IV or SC dose. No serious adverse events or TEAEs leading to discontinuation of treatment were reported. The majority of the TEAEs were mild laboratory test abnormalities, which were asymptomatic and did not require medical intervention. There was no reported case of diarrhea. Activin A was significantly increased in 24 hours following a single intravenous or subcutaneous dose of LAE102. The duration of Activin A elevation was dose-dependent. The high-dose groups (8 mg/kg IV group, 16 mg/kg IV group, and 8 mg/kg SC group) maintained 2-to-3-fold increases above the baseline level through 28 days post-administration, indicating prolonged pathway blocking. The robust PK/PD correlation suggests potential efficacy and supports further clinical development of LAE102 in overweight and obese populations, which established a solid foundation for the Phase I MAD Study. The detailed study results were presented at the 85th scientific sessions of the ADA in June 2025.

The Group commenced study recruitment in the Phase I MAD Study of LAE102 in China by the end of March 2025. The Phase I MAD Study in China is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.

In November 2024, the Group entered into a clinical collaboration agreement with Lilly to support and accelerate global clinical development of LAE102 for the treatment of obesity. Lilly will be responsible for the execution and funding of the U.S. Phase 1 Clinical Trial. The Group retains global rights for LAE102. The Group submitted an IND amendment to the U.S. FDA for LAE102 for the treatment of obesity in March 2025 and dosed the first subject in May 2025. The Group targets to achieve primary completion of the U.S. Phase I Clinical Trial in Q4 2025.

Laekna team has accumulated tremendous experience and extensive knowhow in this specific field and is developing, in addition to LAE102, more drug candidates to maximize the value of targeting ActRII receptors. LAE103 is an ActRIIB-selective antibody and LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody. Both are our internally discovered antibodies for muscle and other disease indications. IND-enabling studies of both antibodies have been initiated in 2024.

The results of the pre-clinical study of LAE102, LAE103 (an ActRIIB selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of ADA. LAE102, LAE103, and LAE123 are high-affinity functional antagonists. They can completely inhibit the signaling transduced by ligands such as activin A, B, AB, and MSTN, all of which are known to contribute to muscle atrophy. In addition, they also inhibit activin E and GDF3, which promote lipid accumulation of adipose tissue. In mouse models, LAE102 alone significantly induced muscle growth and reduced fat mass. Notably, a synergistic effect on muscle increase and fat loss was observed when combining LAE102 with LAE103, achieving the maximal effect comparable to the ActRIIA/IIB dual antagonistic monoclonal antibody. The findings indicate that ActRIIA is a major regulator of muscle growth and fat loss in mice. LAE102 shows great potential as muscle preserving weight loss management with a favorable safety profile. On the other hand, LAE123 could be utilized to treat diseases requiring complete inhibition of both ActRIIA and ActRIIB, such as spinal muscle atrophy.

We submitted IND application to the U.S. FDA for LAE103 by the end of June 2025 and obtained IND approval in July 2025. The Group targets to initiate phase I clinical study of LAE103 in the second half of 2025. In addition to LAE102, the phase I clinical studies of LAE103 enable us to separately evaluate the efficacy and safety of monoclonal antibodies targeting at ActRIIA and ActRIIB in humans. The Group also targets to advance LAE123 to phase I clinical studies in 2026. The Group has established a comprehensive ActRII portfolio and is actively advancing these drug candidates to clinical studies as novel therapies for muscle and other disease indications. We are in discussions with potential partners for strategic cooperations to accelerate development and commercialization of our ActRII portfolio.

LAE002 (afuresertib)

Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. We in-licensed Afuresertib from Novartis in 2018. Prior to our in-licensing, 11 clinical trials had been conducted to demonstrate the safety and efficacy profiles of Afuresertib by Novartis and GSK.

LAE002 (afuresertib) + Fulvestrant in HR+/HER2-breast cancer, Phase III

The Group commenced the Phase III Clinical Trial AFFIRM-205 in China for LAE002 (afuresertib, an oral AKT inhibitor) plus fulvestrant in patients with PIK3CA/AKT1/PTEN alterations and HR+/HER2-LA/mBC in May 2024. The Phase III Clinical Trial AFFIRM-205 is a multi-center, randomized, double-blind, placebo-controlled pivotal study to further assess the anti-tumor efficacy and safety of the combination therapy. Study recruitment is on track. The Group targets to complete subject enrollment in the fourth quarter of 2025 and to submit NDA to CDE in the first half of 2026. We are in discussions with potential partners for strategic cooperations to accelerate regulatory approval and commercialization of LAE002 (afuresertib).

LAE002 (afuresertib) +LAE001/prednisone in mCRPC, Phase II

We completed a Phase II multi-region clinical trial of the study of LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 dual inhibitor) ("**LAE201**") in 40 patients with mCRPC following SOC treatment in 2024. The trial is an open-label, dose-escalation and dose expansion study to assess the efficacy and safety of the combination candidate. The study demonstrated promising treatment benefit for mCRPC patients. The median rPFS was 8.1 months. This is a significant improvement compared to the median rPFS of 2 to 4 months of mCRPC patients under the standard treatments historically. The combination therapy was generally tolerable with manageable treatment emergent adverse events and recoverable after routine treatments.

Design of the Phase III pivotal trial of LAE201 in patients with mCRPC following SOC treatment has been discussed with FDA. In May 2024, the Group has obtained approval from FDA for the protocol of this phase III clinical trial. We plan to pursue strategic partnerships to accelerate the development and commercialization of LAE002 (afuresertib) and LAE001 to address the great unmet medical need of the cancer therapeutic area.

LAE002 (afuresertib) +Paclitaxel for PROC (PROFECTA-II), Phase II

We have initiated a global MRCT Phase II trial (PROFECTA-II) in both the U.S. and China to treat PROC patients with LAE002 (afuresertib) plus paclitaxel. It was a Phase II, randomized, open-label, active-controlled study evaluating the efficacy and safety of LAE002 (afuresertib) in combination with paclitaxel versus paclitaxel in 150 subjects with PROC. In January 2024, we had achieved database lock and announced the top-line data. The study showed reduced risk of disease progression or death (progression-free survival; PFS) with a HR of 0.744 (95% CI: 0.502–1.102) but missed statistical significance. For biomarker subgroup with phospho-AKT positive, IHC>1, (37%), the study data demonstrated that LAE002 (afuresertib) combination arm significantly improved PFS, and the median PFS is 5.4m vs 2.9m with HR of 0.352 (95% CI: 0.125–0.997). The trial has shown a manageable and tolerable safety profile and adverse events were consistent with the known safety profiles of the individual treatments. We plan to pursue strategic partnerships to support further development of this program.

LAE001

LAE001 is an androgen synthesis inhibitor that inhibits both CYP17A1 and CYP11B2. We in-licensed LAE001 from Novartis in 2017. According to Frost & Sullivan, LAE001 is the only dual CYP17A1/CYP11B2 inhibitor in clinical trials for the treatment of prostate cancer globally. As a dual CYP17A1/CYP11B2 inhibitor, LAE001 can block both androgen and aldosterone synthesis and potentially be administrated without prednisone, the short-term high dose or long-term exposure of which can lead to a variety of adverse events.

We completed a Phase I clinical trial of LAE001 as a monotherapy and a Phase II clinical trial of LAE001 plus LAE002 (afuresertib) in patients with mCRPC to assess the safety and efficacy of the therapies. Design of the Phase III pivotal trial of LAE201 in patients with mCRPC following SOC treatment has been discussed with FDA and approval of the same was obtained in May 2024. We plan to pursue strategic partnerships to accelerate the development and commercialization of LAE001 to address the unmet medical need for cancer therapies.

LAE005

LAE005 is a high-affinity, ligand-blocking, humanized anti-PD-L1 IgG4 antibody. In pre-clinical and clinical studies, LAE005 demonstrated its strong binding avidity to PD-L1 and compelling anti-tumor activities. Specifically, we are evaluating the therapeutic potential of the combination therapy of LAE002 (afuresertib) and LAE005 in patients with TNBC. We believe LAE005 has the potential to serve as an effective therapy for the treatment of TNBC when combined with other synergistic mechanisms.

The results of our Phase I clinical trial of LAE002 (afuresertib) in combination with LAE005 (anti-PDL1 mAb) plus nab-paclitaxel for the treatment of triple-negative breast cancer (TNBC) were presented at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in April 2024. A total of 22 subjects with advanced solid tumors were enrolled and dosed in this Phase I study, among which there were 14 TNBC subjects who completed at least 2 cycles of treatment and had at least 1 tumor assessment. The median value of previous treatment lines of these 14 subjects was 1.5 (0-3). Among them, five showed confirmed partial response (ORR 35.7%), four had stable disease (28.6%), resulting in a disease control rate (DCR) of 64.3% in the best response assessment. The median duration of response (DOR) was 9.26 months. Five TNBC subjects were treated for more than 32 weeks, with one subject reaching a duration of 73 weeks. This case study has been selected for the "Chinese Clinical Case Achievement Database" (with the PFS of this case being 16 months as of September 28, 2023). We plan to pursue strategic partnerships to accelerate the development and commercialization of LAE005 to address the unmet medical need for cancer therapies.

CAUTIONARY STATEMENT: WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP OR MARKET THE RELEVANT PRODUCTS, OR ANY OF OUR PIPELINE PRODUCTS, SUCCESSFULLY.

FINANCIAL REVIEW

The following discussion is based on, and should be read in conjunction with, the financial information and notes included elsewhere in this announcement.

Other Income

Our other income increased by RMB5.8 million or 41.1% from RMB14.1 million for the six months ended June 30, 2024 to RMB19.9 million for the six months ended June 30, 2025, which was primarily attributable to the increase in government grants.

Administrative Expenses

Our administrative expenses increased by RMB11.9 million or 39.1% from RMB30.4 million for the six months ended June 30, 2024 to RMB42.3 million for the six months ended June 30, 2025. Such increase was primarily attributable to the increase in equity settled share-based payment expenses.

Research and Development Expenses

Our research and development expenses decreased by RMB20.9 million or 16.6% from RMB126.1 million for the six months ended June 30, 2024 to RMB105.2 million for the six months ended June 30, 2025. Such decrease was primarily attributable to the milestone payment of RMB17.8 million incurred during the first half of 2024 relating to Phase III Clinical Trial AFFIRM-205, while no such expense was incurred during the Reporting Period.

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Staff costs	**41,806**	34,580
Discovery research expenses	**30,392**	13,140
Clinical development expenses	**28,052**	54,417
Clinical trial milestone payment	**–**	17,758
Others	**4,942**	6,253
Total	**105,192**	126,148

Liquidity and Financial Resource

As of June 30, 2025, the current assets of the Group were RMB762.4 million, including cash and cash equivalents of RMB676.6 million, time deposits with an original maturity over three months of RMB67.2 million and other current assets of RMB18.6 million. Among them, the Group's cash and cash equivalents increased by RMB40.2 million or 6.3% to RMB676.6 million as of June 30, 2025 from RMB636.4 million as of December 31, 2024. The Group's time deposits decreased to RMB67.2 million as of June 30, 2025 from RMB163.6 million as of December 31, 2024. As of June 30, 2025, the current liabilities of the Group were RMB194.7 million, including other payables of RMB82.7 million, interest-bearing bank loans of RMB110.0 million and current lease liabilities of RMB2.0 million.

Our cash and bank balances (including cash and cash equivalents and time deposits) as of June 30, 2025 were RMB743.8 million, of which RMB91.7 million, RMB647.4 million and RMB4.7 million were denominated in RMB, USD, and HKD, respectively representing a decrease of 7.0% as compared to the cash and bank balances of RMB800.0 million as of December 31, 2024. The decrease was primarily attributable to the net cash used in operating activities.

Funding and Treasury Policy

The Group adopts a prudent funding and treasury policy, aiming to maintain an optimal financial position and minimal financial risks. We have formulated internal control measures to control our process of investment in wealth management products. Prior to making an investment, we ensure that there remains sufficient working capital for our operations, R&D activities and capital expenditures. For the six months ended June 30, 2025, we funded our operations primarily through equity financing and bank loans. With the continuing expansion of our business and development of new drug candidates, we will use the net proceeds raised from the Global Offering and the Placing and may require further funding through public or private equity offerings, debt financing and other sources.

Bank Loans

Our bank loans as of June 30, 2025 were RMB110.0 million (December 31, 2024: RMB99.0 million), all of which were denominated in RMB and carried interest rates ranging from 2.37% to 3.85% per annum.

Current ratio

Current ratio (calculated by current assets divided by current liabilities) of the Group as of June 30, 2025, was 3.92 (December 31, 2024: 5.48).

Gearing ratio

Gearing ratio is calculated by using interest-bearing borrowings and lease liabilities less cash and cash equivalents, divided by total equity and multiplied by 100%. As of June 30, 2025, the Group was in a net cash position and thus, gearing ratio is not applicable.

Foreign Currency Risk

We have transactional currency exposures. Certain of our cash and bank balances, time deposits, prepayments, other receivables and other payables are denominated in non-functional currencies and exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Contingent Liabilities

As of June 30, 2025, we did not have any material contingent liabilities.

Significant Investments Held

As of June 30, 2025, the Group did not hold any significant investments. Save as disclosed in this announcement, as of June 30, 2025, the Group did not have future plans for material investments and capital assets.

Pledge of Assets

As of June 30, 2025, deposits of RMB4.0 million were pledged to secure issuance of a bank letter of guarantee.

Employees and Remuneration Policies

As of June 30, 2025, the Group had 84 employees. The total employee benefit expenses for the six months ended June 30, 2025, including share-based payment expenses, were RMB77.1 million, as compared to RMB57.3 million for the six months ended June 30, 2024.

Our employees' remuneration comprises salaries, bonuses, provident funds, social security contributions and other welfare payments. We have made contributions to our employees' social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds pursuant to applicable laws and regulations.

We adopted the Post-IPO Share Option Scheme on June 9, 2023, which was immediately prior to Listing. We further adopted the 2024 Share Award Scheme on June 14, 2024. Each of the schemes constitutes a share scheme governed by Chapter 17 of the Listing Rules.

Material Acquisitions and Disposals

During the Reporting Period, the Group did not have any material acquisition or disposal of its subsidiaries, associates and joint ventures.

Use of Net Proceeds from the Global Offering

On June 29, 2023, 63,728,000 shares of US$0.00001 each were issued at a price of HK$12.41 per share in connection with the Company's listing on the Main Board of the Stock Exchange. We intend to apply the net proceeds of HK$724.4 million from the Global Offering as set out in the Prospectus (after deduction of the underwriting fees and commissions and other estimated expenses payable by the Company in connection with the Global Offering).

The below table sets out the proposed and actual applications of the net proceeds from the Listing Date to June 30, 2025.

Intended use of Net Proceeds	**Net Proceeds from the Global Offering** *(HK$ million)*	**Approximate % of total Net Proceeds**	**Unutilized Net Proceeds from the Global Offering as of January 1, 2025** *(HK$ million)*	**Utilized Net Proceeds from the Global Offering during the six months ended June 30, 2025** *(HK$ million)*	**Utilized Net Proceeds from the Global Offering as of June 30, 2025** *(HK$ million)*	**Unutilized Net Proceeds from the Global Offering as of June 30, 2025** *(HK$ million)*	**Expected timeline of full utilization of the unutilized Net Proceeds**[(1)]
For rapidly advancing the clinical development and approval of our Core Products, i.e. LAE001 and LAE002 (afuresertib)	407.8	56.3%	181.0	42.9	269.7	138.1	Before December 31, 2026
For accelerating the research and development of other existing pipeline products and continuously advancing and improving our pipeline products	150.7	20.8%	35.6	29.3	144.4	6.3	Before December 31, 2025
For improving our production capabilities and developing our manufacturing capacities	71.7	9.9%	66.8	–	4.9	66.8	Before December 31, 2027
For business development activities and enhancing our global reach	55.1	7.6%	34.7	6.3	26.7	28.4	Before December 31, 2027
For working capital and other general corporate purposes	39.1	5.4%	–	–	39.1	–	

Note:

(1) The expected timeline is based on the best estimation made by the Group on future market condition and may change with the future market condition and future development.

Use of Net Proceeds from the Placing

On November 27, 2024, the Company completed a placing of an aggregate of 17,636,000 Placing Shares by the Sole Placing Agent to not less than six Placees at a price of HK$13.36 per Placing Share pursuant to the terms and conditions of the Placing Agreement. The gross proceeds from the Placing were approximately HK$235.6 million. The Company received net proceeds from the Placing, after deducting the placing commission and other related expenses and professional fees, of approximately HK$230.4 million. The net proceeds from the Placing were used during the Reporting Period, and the unutilized net proceeds are intended to be used, in accordance with the intended use of proceeds as previously set out in the announcement of the Company dated November 21, 2024.

The below table sets out the proposed and actual applications of the net proceeds during the Reporting Period:

Intended use of Net Proceeds	Net Proceeds from the Placing *(HK$ million)*	Approximate % of total Net Proceeds	Unutilized Net Proceeds from the Placing as of January 1, 2025 *(HK$ million)*	Utilized Net Proceeds from the Placing during the six months ended June 30, 2025 *(HK$ million)*	Utilized Net Proceeds from the Placing as of June 30, 2025 *(HK$ million)*	Unutilized Net Proceeds from the Placing as of June 30, 2025 *(HK$ million)*	Expected timeline of full utilization of the unutilized Net Proceeds[(1)]
For accelerating research and development of LAE102 and other drug assets targeting ActRII receptors	230.4	100%	228.3	49.6	51.6	178.7	Before December 31, 2026

Note:

(1) The expected timeline is based on the best estimation made by the Group on future market condition and may change with the future market condition and future development.

FUTURE DEVELOPMENT

We will continue to advance and expand our product portfolio in the therapeutic areas where we have accumulated tremendous experience and extensive know-how.

LAE102 is our internally discovered monoclonal antibody against ActRIIA. Blocking Activin-ActRII pathway could promote skeletal muscle regeneration and fat mass reduction, and this positions LAE102 as a promising drug candidate for achieving muscle preserving weight control. LAE103 is an ActRIIB-selective antibody and LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody. Both are our internally discovered antibodies for muscle and other disease indications. The Group has established a comprehensive ActRII portfolio and strives to maximize the value of targeting ActRII receptors.

We are in the process of developing multiple innovative drug candidates, including small molecules, bispecific antibodies, and bifunctional NK engagers against various diseases. We aim to advance our pipeline to address the unmet medical need of underserved patients and target to have one drug candidate entering the clinical stage each year.

The Group also actively explores potential combination therapy opportunities among our pipeline and with existing approved drugs as well as conventional therapies. Our LAE002 (afuresertib) combination trial with Fulvestrant has demonstrated remarkable clinical value to treat HR+/HER2- breast cancer patients who have failed previous standard of care treatments of endocrine/anti-estrogen therapies, including CDK4/6 inhibitors which represent a big unmet medical need with huge market potential. Our combination therapy of LAE002 (afuresertib) plus LAE001 to treat the second-generation A/AR drug-resistant mCRPC also demonstrated promising treatment benefits to mCRPC patients. We are committed to unleashing the clinical values of our drug candidates.

During the Reporting Period, the Group was working together with Lilly to accelerate global clinical development of LAE102 for the treatment of obesity. We plan to pursue more strategic partnerships with global leading pharmaceutical companies to accelerate clinical development and commercialization of our drug candidate assets. We keep advancing and expanding our pipeline and are committed to bringing life-changing medicines to more people around the world.

CORPORATE GOVERNANCE RELATED INFORMATION

Compliance with Corporate Governance Code

The Company recognizes the importance of good corporate governance for enhancing the management of the Company as well as preserving the interests of the Shareholders as a whole. The Company has adopted the CG Code contained in Appendix C1 to the Listing Rules as its own code of corporate governance. The Directors are of the view that during the Reporting Period, the Company has complied with all applicable code provisions of the CG Code save and except for the following deviation from code provision C.2.1 of the CG Code.

Under code provision C.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Dr. LU Chris Xiangyang ("**Dr. Lu**") has served as our chairman since May 2018 and chief executive officer since April 2017. Dr. Lu is the founder of our Group and has extensive experience in the business operations and management of our Group. Our Board believes that, in view of his experience, personal profile and his roles in our Company as mentioned, Dr. Lu is the Director best suited to identify strategic opportunities and focus of the Board due to his extensive understanding of our business as our chief executive officer. Our Board also believes that the combined role of chairman and chief executive officer can promote the effective execution of strategic initiatives and facilitate the flow of information between management and the Board. Our Directors consider that the balance of power and authority will not be impaired due to this arrangement. In addition, all major decisions are made in consultation with members of the Board, including the relevant Board committees, and three independent non-executive Directors.

The Board will continue to review the effectiveness of the corporate governance structure of the Group in order to assess whether separation of the roles of chairman and the chief executive officer is necessary.

Compliance with the Model Code for Securities Transactions

The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors and the Company's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company or its securities.

Upon specific enquiry, all Directors confirmed that they have complied with the Model Code during the Reporting Period. In addition, the Company is not aware of any non-compliance of the Model Code by the employees of the Company who are likely to be in possession of inside information of the Company during the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities (including sale of treasury shares (as defined under the Listing Rules)) during the Reporting Period. As of June 30, 2025, the Company did not hold any treasury shares (as defined under the Listing Rules).

AUDIT COMMITTEE AND REVIEW OF INTERIM RESULTS

The Company has established an Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Group, overseeing the audit process and performing other duties and responsibilities as assigned by the Board. The Audit Committee currently consists of two independent non-executive Directors being Mr. ZHOU Jian and Dr. LI Min, and one non-executive Director being Dr. WANG David Guowei. The chairperson of the Audit Committee is Mr. ZHOU Jian. Mr. ZHOU Jian holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing rules.

The Audit Committee had reviewed, together with the management, the accounting principles and policies adopted by the Group and discussed internal controls and financial reporting matters including a review of the unaudited interim financial information of the Group for the Reporting Period.

In addition, the Company's independent auditor, KPMG, has performed an independent review of the Group's interim financial information for the Reporting Period in accordance with Hong Kong Standard on Review Engagements 2410 "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*" issued by the Hong Kong Institute of Certified Public Accountants.

EVENTS AFTER THE REPORTING PERIOD

Save as disclosed in this announcement and as at the date of this announcement, there were no material subsequent events after the Reporting Period.

INTERIM DIVIDEND

The Board does not declare the payment of an interim dividend to the Shareholders for the Reporting Period.

PUBLICATION OF RESULTS ANNOUNCEMENT AND INTERIM REPORT

This announcement is published on the website of the Stock Exchange at www.hkexnews.hk and on the website of the Company at www.laekna.com. The interim report of the Company for the six months ended June 30, 2025 containing all the information required by the Listing Rules will be published on the same websites and dispatched (if requested) to the Shareholders in due course.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following respective meanings:

"AE"	adverse events, any untoward medical occurrences in a patient or clinical investigation subject administered a drug or other pharmaceutical product during clinical trials and which do not necessarily have a causal relationship with the treatment
"AKT"	a serine/threonine protein kinase with 3 isoforms (AKT1, AKT2 and AKT3) that participate in multiple pathways regulating several cellular processes, including survival, proliferation, tissue invasion, and metabolism
"Audit Committee"	the audit committee of the Board
"Board"	the board of directors of our Company
"CDE"	the center for drug evaluation of China's National Medical Products Administration
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"China" or "PRC"	the People's Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires otherwise, references in this announcement to "China" and the "PRC" do not apply to Hong Kong Special Administrative Region of the People's Republic of China, Macau Special Administrative Region of the People's Republic of China and Taiwan, China
"CMC"	chemistry, manufacture and control

"Company" or "Our Company"	Laekna, Inc. (來凱醫藥有限公司), an exempted company incorporated in the Cayman Islands with limited liability on July 29, 2016
"Director(s)" or "our Director(s)"	the directors of the Company
"ESOP Trusts"	Laekna Halley Trust and Laekna Wonderland Trust, being the trusts set up by the Company to facilitate the administration of the Pre-IPO Share Option Scheme
"FDA"	the United States Food and Drug Administration
"Global Offering"	the Hong Kong Public Offering and the International Offering
"Group", "our Group", "we", "us" or "our"	our Company and its subsidiaries
"HK$" or "HKD"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"HR+/HER2-breast cancer"	the most common type of breast cancer with overexpression of HR and without overexpression of HER2
"IHC"	immunohistochemistry, a test that uses a chemical dye to stain and measure specific proteins
"IND"	investigational new drug, the application for which is the first step in the drug review process by regulatory authorities to decide whether to permit clinical trials; also known as clinical trial application, or CTA, in China
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange
"Listing Date"	June 29, 2023
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time

"mCRPC"	metastatic castration resistant prostate cancer
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
"MRCT"	multi-regional clinical trials
"NDA"	new drug application
"NMPA"	China's National Medical Products Administration (中國國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (中國國家食品藥品監督管理總局)
"Novartis"	Novartis Pharma AG, a company organized under the laws of Switzerland and one of our Pre-IPO Investors
"PCC"	pre-clinical candidate
"PD-1"	programmed cell death protein 1
"PFS"	progression-free survival, the length of time during and after the treatment of a disease, such as cancer, that a patient lives without the disease getting worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works
"Placee(s)"	any individuals, corporate, institutional or other investor(s) procured by the Sole Placing Agent or their respective agents to subscribe for any of the Placing Shares pursuant to the Placing Agreement
"Placing"	the placing of 17,636,000 Placing Shares pursuant to the terms of the Placing Agreement
"Placing Agreement"	the conditional placing agreement entered into between the Company and the Sole Placing Agent dated November 21, 2024 in relation to the Placing
"Placing Shares"	17,636,000 shares placed pursuant to the Placing Agreement

"Pre-IPO Share Option Scheme"	the share option scheme adopted by our Company on April 11, 2018 and amended on October 30, 2019, April 20, 2021 and March 31, 2022, as amended from time to time
"PROC"	platinum resistant ovarian cancer
"Prospectus"	the prospectus of the Company dated June 16, 2023
"Reporting Period"	the six months ended June 30, 2025
"RMB"	Renminbi, the lawful currency of China
"rPFS"	radiographic progression free survival
"RP2D"	recommended Phase II dose
"SAE"	serious AE, any medical occurrence in human drug trials that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage
"Share(s)"	ordinary share(s) in the share capital of our Company with a par value of US$0.00001 each
"Shareholder(s)"	holder(s) of Shares
"SOC"	treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by healthcare professionals
"Sole Placing Agent"	CLSA Limited, being the sole placing agent and sole overall coordinator of the Placing
"South Korea"	the Republic of Korea
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"TEAE"	adverse events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment

"TNBC"	triple-negative breast cancer, any breast cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2
"treasury shares"	has the meaning as defined under the Listing Rules
"United States", "USA" or "U.S."	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"US$" or "USD"	United States dollars, the lawful currency of the United States
"%"	per cent

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, August 13, 2025

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.